TheraRadar
Data updated: Jun 28, 2026

TOUJEO MAX SOLOSTAR (insulin glargine recombinant) · Sanofi

Metabolic Approved 2015-02-25

TOUJEO MAX SOLOSTAR is FDA-approved to treat 1 condition (same as LANTUS SOLOSTAR).

2
Indications
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2015-02-25
Routes
SUBCUTANEOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: INSULIN GLARGINE RECOMBINANT

TOUJEO MAX SOLOSTAR Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
12 FDA actions from 2015 to 2024 · 1 indication expansions
Aug 2024 SUPPL
Label · Labeling
Aug 2022 SUPPL
Label · Labeling
Nov 2019 SUPPL
Efficacy

What TOUJEO MAX SOLOSTAR Treats

1 indications

TOUJEO MAX SOLOSTAR is approved for 1 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.

Same approved indications as LANTUS SOLOSTAR (same active ingredient).

Source: FDA Label
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT00943709 060601 AVENTIS-CINJ-060601, 0220070268 Ph 3 withdrawn Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TOUJEO MAX SOLOSTAR FDA Label Details

Indications & Usage

FDA Label (PDF)

TOUJEO MAX SOLOSTAR is FDA-approved to treat 1 condition — same approved indications as LANTUS SOLOSTAR.

Track TOUJEO MAX SOLOSTAR with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.